Alto Neuroscience announces new patent for depression treatment

Alto Neuroscience, a clinical-stage biopharmaceutical company specialising in precision treatments for neuropsychiatric conditions, has announced the issuance of a US patent for methods of treating depression with Alto’s ALTO-207 (pramipexole and ondansetron). The patent protects the use of ondansetron to reduce side effects associated with pramipexole, allowing patients to take higher doses of pramipexole and […] The post Alto Neuroscience announces new patent for depression treatment appeared first on Pharmafile.

Continue reading →